Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2025 07:00 ET | Source: Transpire Bio

Transpire Bio Enters into Exclusive License Agreement with Suzhou Intragrand Pharma for Investigational PDE4 Inhibitor

Transpire Bio Inc. has signed an exclusive license agreement with Suzhou Intragrand Pharma Co. for an investigational PDE4 inhibitor
November 01, 2023 02:20 ET | Source: Spexis AG

Spexis Announces Changes to the Executive Committee

Spexis Announces Changes to the Executive Committee
September 29, 2023 01:30 ET | Source: Spexis AG

Spexis provides business update and announces financial results for the first half of 2023

Spexis provides business update and announces financial results for the first half of 2023
September 28, 2023 01:30 ET | Source: Spexis AG

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
June 30, 2023 01:15 ET | Source: Spexis AG

Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions

Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and...
May 30, 2023 01:15 ET | Source: Spexis AG

Spexis provides business update and announces financial results for the full year 2022

Ad hoc announcement pursuant to Art. 53 LR USD 4.5 million capital commitment from SPRIM Global Investments to enable initiation of ColiFin® COPILOT study; first patient dosing expected in...
April 18, 2023 02:23 ET | Source: Spexis AG

Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study

Ad hoc announcement pursuant to Art. 53 LR Funding to enable immediate initiation of the COPILOT study, the first of two Phase 3 ColiFin® studies; first-patient-in expected in June 2023Commitment...
December 29, 2021 02:30 ET | Source: EnBiotix, Inc.

EnBiotix, Inc. Closes $11M Pre-Merger Financing

BOSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) -- EnBiotix, Inc., a rare disease company currently focused on chronic respiratory disorders, today announced the closing of an $11M pre-merger, convertible...